Chee Wah Tan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2316393/publications.pdf

Version: 2024-02-01

40	4,563	279798 23	265206 42
papers	citations	h-index	g-index

48	48	48	9751
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clinical Microbiology and Infection, 2022, 28, 612.e1-612.e7.	6.0	231
2	Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2 Infection In Vitro , despite Eliciting a Prolonged Antiviral Response. MBio, 2022, 13, e0343621.	4.1	12
3	Decreased memory B cell frequencies in COVIDâ€19 delta variant vaccine breakthrough infection. EMBO Molecular Medicine, 2022, 14, e15227.	6.9	31
4	WHO international standard for SARS-CoV-2 antibodies to determine markers of protection. Lancet Microbe, The, 2022, 3, e81-e82.	7.3	56
5	Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers. Vaccines, 2022, 10, 639.	4.4	18
6	Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial. Clinical Infectious Diseases, 2022, 75, 2088-2096.	5.8	23
7	Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. Clinical Infectious Diseases, 2021, 73, e2932-e2942.	5.8	143
8	Low postpandemic wave SARSâ€CoVâ€2 seroprevalence in Kuala Lumpur and Selangor, Malaysia. Journal of Medical Virology, 2021, 93, 647-648.	5.0	19
9	Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia. Nature Communications, 2021, 12, 972.	12.8	276
10	Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Reports, 2021, 34, 108728.	6.4	568
11	Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand. PLoS ONE, 2021, 16, e0246864.	2.5	20
12	Vaccine candidates generated by codon and codon pair deoptimization of enterovirus A71 protect against lethal challenge in mice. Vaccine, 2021, 39, 1708-1720.	3.8	7
13	Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe, The, 2021, 2, e240-e249.	7.3	322
14	Bat virome research: the past, the present and the future. Current Opinion in Virology, 2021, 49, 68-80.	5.4	17
15	SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness. Scientific Reports, 2021, 11, 2062.	3.3	58
16	Identification of ZDHHC17 as a Potential Drug Target for Swine Acute Diarrhea Syndrome Coronavirus Infection. MBio, 2021, 12, e0234221.	4.1	11
17	Neutralizing Activity and SARS-CoV-2 Vaccine mRNA Persistence in Serum and Breastmilk After BNT162b2 Vaccination in Lactating Women. Frontiers in Immunology, 2021, 12, 783975.	4.8	29
18	A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2â€“spike proteinâ€“protein interaction. Nature Biotechnology, 2020, 38, 1073-1078.	17.5	1,042

#	Article	IF	Citations
19	Discovery and Genomic Characterization of a 382-Nucleotide Deletion in ORF7b and ORF8 during the Early Evolution of SARS-CoV-2. MBio, 2020, 11, .	4.1	245
20	Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Emerging Microbes and Infections, 2020, 9, 900-902.	6.5	89
21	Serological differentiation between COVID-19 and SARS infections. Emerging Microbes and Infections, 2020, 9, 1497-1505.	6.5	89
22	Connecting clusters of COVID-19: an epidemiological and serological investigation. Lancet Infectious Diseases, The, 2020, 20, 809-815.	9.1	229
23	Infection of human Nasal Epithelial Cells with SARS-CoV-2 and a 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host transcriptional profiles. PLoS Pathogens, 2020, 16, e1009130.	4.7	98
24	An unusual COVID-19 case with over four months of viral shedding in the presence of low neutralizing antibodies: a case report. Journal of Biomedical Research, 2020, 34, 470.	1.6	8
25	Immune responses against enterovirus A71 infection: Implications for vaccine success. Reviews in Medical Virology, 2019, 29, e2073.	8.3	18
26	Electrostatic interactions at the five-fold axis alter heparin-binding phenotype and drive enterovirus A71 virulence in mice. PLoS Pathogens, 2019, 15, e1007863.	4.7	22
27	Serological evidence and experimental infection of cynomolgus macaques with pteropine orthoreovirus reveal monkeys as potential hosts for transmission to humans. Emerging Microbes and Infections, 2019, 8, 787-795.	6.5	8
28	Cell surface Î±2,3-linked sialic acid facilitates Zika virus internalization. Emerging Microbes and Infections, 2019, 8, 426-437.	6.5	29
29	Dampened NLRP3-mediated inflammation in bats and implications for a special viral reservoir host. Nature Microbiology, 2019, 4, 789-799.	13.3	245
30	Serological evidence of human infection by bat orthoreovirus in Singapore. Journal of Medical Virology, 2019, 91, 707-710.	5.0	18
31	Characterization of a filovirus (MÄ›nglÃ virus) from Rousettus bats in China. Nature Microbiology, 2019, 4, 390-395.	13.3	116
32	Identification and characterization of neutralization epitopes at VP2 and VP1 of enterovirus A71. Journal of Medical Virology, 2018, 90, 1164-1167.	5.0	3
33	Serological Cross Reactivity between Zika and Dengue Viruses in Experimentally Infected Monkeys. Virologica Sinica, 2018, 33, 378-381.	3.0	4
34	Polysulfonate suramin inhibits Zika virus infection. Antiviral Research, 2017, 143, 186-194.	4.1	67
35	VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction. Virology, 2017, 501, 79-87.	2.4	51
36	Enterovirus A71 DNA-Launched Infectious Clone as a Robust Reverse Genetic Tool. PLoS ONE, 2016, 11, e0162771.	2.5	27

#	Article	IF	Citations
37	Inhibition of enterovirus 71 infection by antisense octaguanidinium dendrimer-conjugated morpholino oligomers. Antiviral Research, 2014, 107, 35-41.	4.1	14
38	Enterovirus 71 Uses Cell Surface Heparan Sulfate Glycosaminoglycan as an Attachment Receptor. Journal of Virology, 2013, 87, 611-620.	3.4	183
39	Enterovirus 71 receptors: promising drug targets?. Expert Review of Anti-Infective Therapy, 2013, 11, 547-549.	4.4	2
40	Inhibition of Enterovirus 71 (EV-71) Infections by a Novel Antiviral Peptide Derived from EV-71 Capsid Protein VP1. PLoS ONE, 2012, 7, e34589.	2.5	41